Citations

Showing 10 of 108094 citations.

Evaluation of 2 breast cancer risk models in a benign breast disease cohort
Frank, Ryan D. , Vierkant, Robert A. , Frost, Marlene H., Ghosh, Karthik, Brandt, Kathleen R. , Visscher, Daniel W., Hartmann, Lynn C. , Vachon, Celine M. , Radisky, Derek C. , Degnim, Amy C , Vachon, Celine M. , Vierkant, Robert A , Winham, Stacey J. , Sherman, Mark E. , Degnim, Amy C.

Mayo Clinic

Cancer | June 22, 2018 | Volume: 124 | Issue: 16 | Pages: 3319-3328

10.1002/cncr.31528 | PMID 29932456 Get It

Background More than 1.5 million women per year have a benign breast biopsy resulting in concern about their future breast cancer (BC) risk. This study examined the performance of 2 BC risk models that integrate clinical and histologic findings in this population. Methods The BC risk at 5 and 10 years was estimated with the Breast Cancer Surveillance Consortium (BCSC) and Benign Breast Disease to Breast Cancer (BBD‐BC) models for women diagnosed with benign breast disease (BBD) at the Mayo Clinic from 1997 to 2001. Women with BBD were eligible for the BBD‐BC model, but the BCSC model also required a screening mammogram. Calibration and discrimination were assessed. Results Fifty‐six cases of BC were diagnosed among the 2142 women with BBD (median age, 50 years) within 5 years (118 were diagnosed within 10 years). The BBD‐BC model had slightly better calibration at 5 years (0.89; 95% confidence interval [CI], 0.71‐1.21) versus 10 years (0.81; 95% CI, 0.70‐1.00) but similar discrimination in the 2 time periods: 0.68 (95% CI, 0.60‐0.75) and 0.66 (95% CI, 0.60‐0.71), respectively. In contrast, among the 1089 women with screening mammograms (98 cases of BC within 10 years), the BCSC model had better calibration (0.94; 95% CI, 0.85‐1.43) and discrimination (0.63; 95% CI, 0.56‐0.71) at 10 years versus 5 years (calibration, 1.31; 95% CI, 0.94‐2.25; discrimination, 0.59; 95% CI, 0.46‐0.71) where discrimination was not different from chance. Conclusions The BCSC and BBD‐BC models were validated in the Mayo BBD cohort, although their performance differed by 5‐year risk versus 10‐year risk. Further enhancement of these models is needed to provide accurate BC risk estimates for women with BBD.
Endoscope-assisted contralateral transmaxillary approach to the clivus and the hypoglossal canal: technical case report
Pamias-Portalatin, Eva, Mahato, Deependra, Rincón-Torroella, Jordina , Vivas-Buitrago, Tito , Quiñones‐Hinojosa, Alfredo , Boahene, Kofi O.

Mayo Clinic

Journal of Neurosurgery | June 22, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.3171/2018.1.jns171972 | PMID 29932381 Get It

Clival lesions are still considered surgically complex due to their anatomical location. Critical structures, such as the internal carotid arteries (ICAs), cavernous sinuses, cranial nerves, and brainstem, may be encased within the lesion. Although advances in endoscopic endonasal approaches have provided new routes to these lesions, exposure and resection of clival tumors through the endonasal route remain a technical challenge. Here, the authors report a left-sided endoscopic transmaxillary approach to access the right aspect of the clivus and the hypoglossal canal. A 35-year-old woman presented with progressive right 6th cranial nerve palsy. MRI revealed a contrast-enhancing right petroclival chondrosarcoma that involved Meckel’s cave and extended into the right hypoglossal canal. An endoscopic-contralateral-transmaxillary approach through a left sublabial incision was used to access the right petroclival region and right hypoglossal canal. A left maxillary osteoplastic flap was elevated to expose the left maxillary sinus. This was followed by a left medial maxillectomy, gaining access to the left posterior nasal cavity. The posterior third of the left inferior turbinate and nasal septum were removed to access the right side of the petroclival region. Near-total resection was achieved without any vascular or neurological complications. A thin shell of residual tumor was left behind due to involvement of vital structures, such as the ICA, and further treated with proton-beam radiotherapy. The endoscopic-contralateral-transmaxillary approach provides a direct surgical corridor and good lateral visualization of the skull base vasculature. This approach allows wide maneuverability around the ICA and hypoglossal canal, which, in this case, allowed maximal tumor resection with full preservation of neurological function.
The Strengths and Limitations of E/E' in Heart Failure with Preserved Ejection Fraction
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

European Journal of Heart Failure | June 22, 2018 | Volume: 20 | Issue: 9 | Pages: 1312-1314

10.1002/ejhf.1250 | PMID 29932475 Get It

H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
Dong, Fang , Gan, Haiyun , Cheng, Liang , Lee, Jeong‐Heon , Zhou, Hui , Zhang, Zhiguo , Fang, Dong , Zhang, Zhiguo , Lee, Jeong-Heon , Sarkaria, Jann N. , Daniels, David J.

Mayo Clinic

eLife | June 22, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.36696 | PMID 29932419 Get It

Expression of histone H3.3K27M mutant proteins in human diffuse intrinsic pontine glioma (DIPG) results in a global reduction of tri-methylation of H3K27 (H3K27me3), and paradoxically, H3K27me3 peaks remain at hundreds of genomic loci, a dichotomous change that lacks mechanistic insights. Here, we show that the PRC2 complex is sequestered at poised enhancers, but not at active promoters with high levels of H3.3K27M proteins, thereby contributing to the global reduction of H3K27me3. Moreover, the levels of H3.3K27M proteins are low at the retained H3K27me3 peaks and consequently having minimal effects on the PRC2 activity at these loci. H3K27me3-mediated silencing at specific tumor suppressor genes, including Wilms Tumor 1, promotes proliferation of DIPG cells. These results support a model in which the PRC2 complex is redistributed to poised enhancers in H3.3K27M mutant cells and contributes to tumorigenesis in part by locally enhancing H3K27me3, and hence silencing of tumor suppressor genes.
Follistatin‐like protein 1 induction of matrix metalloproteinase 1, 3 and 13 gene expression in rheumatoid arthritis synoviocytes requires MAPK, JAK/STAT3 and NF‐κB pathways
Ni, Su , Li, Chenkai , Xu, Nanwei , Wang, Wei , Wang, Yuji , Wijnen, André J. van , van Wijnen, Andre J , Liu, Xi , Chen, Wenyang

Mayo Clinic

Journal of Cellular Physiology | June 22, 2018 | Volume: 234 | Issue: 1 | Pages: 454-463

10.1002/jcp.26580 | PMID 29932210 Get It

Elevated levels of follistatin‐like protein 1 (FSTL1) have been found both in mouse models for human rheumatoid arthritis (RA) and collagen‐induced arthritis (CIA). In this study, we elucidated the potential mechanisms by which FSTL1 contributes to the pathogenesis of RA. Fibroblast‐like synoviocytes (FLSs) were established from synovial tissues of RA patients and stimulated with human recombinant FSTL1. Protein and mRNA expression levels of select matrix metalloproteinases (i.e., MMP1, MMP3, MMP13) in FLS were measured by, respectively, real‐time RT‐qPCR and ELISA. Activation of MAPK and other pathways that affect MMPs were evaluated by Western blotting. We also compared concentrations of MMPs in plasma in RA patients versus healthy controls (HC). Expression levels of MMP1, MMP3, and MMP13 were clearly stimulated by FSTL1 in vitro. FSTL1 activated the inflammation‐related NF‐κB signaling pathway, as well as all three mitogen‐activated protein kinase (MAPK) pathways and the JAK/STAT3 pathway. Moreover, select chemical inhibitors that target p38 (SB203580), Erk1/2 (SP600125), JNK (SCH772984), STAT3 (AG490), and NF‐κB (BAY 11–7082) significantly attenuated MMP expression. Inhibition of Toll‐like receptor 4 by compound TAK‐242 significantly abolished those effects of FSTL1. Importantly, elevated plasma concentrations of MMP3 were found to correlate with plasma FSTL1 levels in RA patients. These findings suggest that FSTL1 accelerates RA progression by activating MAPK, JAK/STAT3, and NF‐κB pathways to enhance secretion of different MMPs and this enhancement is via TLR4. Targeting FSTL1 may provide a promising pharmacological drug therapy to ameliorate RA symptoms and perhaps reverse disease progression.
Spinal Fusions in Active Military Personnel: Who Gets a Lumbar Spinal Fusion in the Military and What Impact Does It Have on Service Member Retention?
Robinson, William A. , Carlson, Bayard C. , Schulte, Spencer , Petfield, Joseph L. , Freedman, Brett A. , Hevesi, Mario

Mayo Clinic

Military Medicine | June 22, 2018 | Volume: 184 | Issue: 1-2 | Pages: e156-e161

10.1093/milmed/usy139 | PMID 30690620 Get It

Florid dermatopathic lymphadenopathy—A morphological mimic of Langerhans cell histiocytosis
Ravindran, Aishwarya , Goyal, Gaurav , Failing, Jarrett, Failing, Jarrett J, Goyal, Guarav , Ravindran, Aishwarya , Go, Ronald S. , Rech, Karen L.

Mayo Clinic

Clinical Case Reports | June 22, 2018 | Volume: 6 | Issue: 8 | Pages: 1637-1638

10.1002/ccr3.1663 | PMID 30147924 Get It

Key Clinical Message The histopathology of reactive florid dermatopathic lymphadenopathy shows overlap with Langerhans cell histiocytosis ( LCH ) involving the lymph node, which may lead to misdiagnosis. These entities can be distinguished by recognition of the sinus‐based distribution of Langerhans cells in LCH , in contrast to the paracortical distribution of Langerhans cells, pigment‐laden histiocytes, and small lymphocytes in dermatopathic lymphadenopathy.
Standardized classification and reporting of glomerulonephritis
Sethi, Sanjeev , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | June 21, 2018 | Volume: 34 | Issue: 2 | Pages: 193-199

10.1093/ndt/gfy220 | PMID 30124958 Get It

Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn’s Disease: Results from IMAgINE 1 and IMAgINE 2
Ruemmele, Frank M. , Rosh, Joel R. , Faubion, William A. , Dubinsky, Marla C. , Turner, Dan , Lazar, Andreas, Eichner, Samantha, Maa, Jen‐Fue, Alperovich, Gabriela , Robinson, Anne, Hyams, Jeffrey S.

Mayo Clinic

Journal of Crohn's and Colitis | June 21, 2018 | Volume: 12 | Issue: 10 | Pages: 1249-1254

10.1093/ecco-jcc/jjy087 | PMID 29939254 Get It